News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

Al's Comment:

 This H3 K27M mutation is a marker for the worst prognostic group of brain tumors, and as far as I know, this is the first drug in clinical trials to target this mutation.  Aside from being present in some of the worst GBMs, it is present in most DIPG tumors.


Posted on: 11/24/2017

Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc